RESUMO
BACKGROUND: Due to an increasing occupational usage of isothiazolinone (IT)-containing preservatives, and their potential to cause skin sensitization and allergic contact dermatitis, that is, chronic disease, there is a need for more knowledge on how highly exposed workers are affected. OBJECTIVES: The overall objective was to explore dermatological symptoms of potentially long-lasting or chronic character in Swedish painters. METHODS: Building painters from western and southern Sweden were initially invited to perform a questionnaire on occurrence of skin symptoms. Participants with affirmative responses, and the right inclusion criteria, were further invited to patch testing with four different ITs: benzisothiazolinone (BIT), methylisothiazolinone, methylchloroisothiazolinone and octylisothiazolinone. RESULTS: There was a tendency towards higher occurrence of positive patch test reactions among the painters compared with occupationally unexposed registry patients; however, not statistically significant differences. BIT was the substance most frequently causing positive test results in both groups. The occurrence of adult-onset eczema was higher in painters than in the control group of electricians, and just shy of statistical significance concerning any of several skin locations (face/legs/arms/hands). CONCLUSION: Building painters present with positive patch test reactions to common paint preservatives (ITs), and they report adult-onset eczema more often than do less occupationally exposed groups.
Assuntos
Dermatite Alérgica de Contato , Dermatite Ocupacional , Eczema , Exposição Ocupacional , Pintura , Testes do Emplastro , Conservantes Farmacêuticos , Tiazóis , Humanos , Tiazóis/efeitos adversos , Suécia/epidemiologia , Dermatite Alérgica de Contato/etiologia , Dermatite Alérgica de Contato/diagnóstico , Dermatite Ocupacional/etiologia , Dermatite Ocupacional/diagnóstico , Dermatite Ocupacional/epidemiologia , Masculino , Adulto , Pessoa de Meia-Idade , Conservantes Farmacêuticos/efeitos adversos , Exposição Ocupacional/efeitos adversos , Eczema/induzido quimicamente , Eczema/epidemiologia , Feminino , Pintura/efeitos adversos , Autorrelato , Inquéritos e QuestionáriosRESUMO
BACKGROUND: A high incidence of local itching subcutaneous nodules and aluminium allergy was observed in clinical trials of a new aluminium adsorbed pertussis vaccine in Gothenburg, Sweden, in the 1990s. A total of 495 children with itching nodules were patch tested with aluminium chloride hexahydrate 2% and an empty Finn Chamber®, 377 (76%) with positive reactions. When 241 of them were re-tested some years later 186 (3 out of 4) had unexpectedly lost their patch test reactivity. AIM: To investigate the long-term prognosis of vaccine-induced contact allergy to aluminium by a third patch test about 20 years after Patch test I. METHODS: Twenty individuals with positive and 11 with negative results in Patch test II were tested a third time with the same sensitisers as in in the first two tests. Three additional aluminium preparations were also tested. RESULTS: A total 15 out of 20 persons with positive results in the second test had lost their patch test reactivity. Two of 11 with negative tests had turned positive again. The addition of the preparations gave no conclusive results. CONCLUSION: Contact allergy to aluminium caused by vaccination with aluminium-adsorbed vaccines in childhood seems to fade away with time as measured by loss of patch test reactivity.
Assuntos
Dermatite Alérgica de Contato , Vacina contra Coqueluche , Criança , Humanos , Alumínio/efeitos adversos , Dermatite Alérgica de Contato/diagnóstico , Dermatite Alérgica de Contato/etiologia , Testes do Emplastro/métodos , Prognóstico , Prurido , Habilidades para Realização de Testes , Vacina contra Coqueluche/efeitos adversosRESUMO
BACKGROUND: According to studies on adults, patch testing with aluminium chloride hexahydrate 2% pet. is insufficient to detect aluminium allergy, and a 10% preparation is recommended. Other studies suggest that a 2% preparation is sufficient for testing children. OBJECTIVES: To review three previously published Swedish studies on patch testing children with aluminium chloride hexahydrate 2% pet. PATIENTS/METHODS: Altogether, 601 children with persistent itching subcutaneous nodules (granulomas) induced by aluminium-adsorbed vaccines were patch tested with aluminium chloride hexahydrate 2% pet. and metallic aluminium in (a) a pertussis vaccine trial, (b) clinical practice, and (c) a prospective study. RESULTS: Overall, 459 children had positive reactions to the 2% pet. preparation. Another 10 reacted positively only to metallic aluminium. An extreme positive reaction (+++) was seen in 65% of children aged 1 to 2 years as compared with 22% of children aged 7 years. From 8 years onwards, extreme positive reactions were scarce. CONCLUSIONS: Aluminium chloride hexahydrate 2% pet. is sufficient to trace aluminium allergy in children. Small children are at risk of extreme reactions. We thus suggest that aluminium chloride hexahydrate 10% pet. should not be used routinely in children before the age of 7 to 8 years.
Assuntos
Alérgenos/administração & dosagem , Cloreto de Alumínio/administração & dosagem , Dermatite Alérgica de Contato/diagnóstico , Testes do Emplastro/métodos , Alérgenos/efeitos adversos , Cloreto de Alumínio/efeitos adversos , Criança , Dermatite Alérgica de Contato/etiologia , HumanosRESUMO
BACKGROUND: An aluminium hydroxide-adsorbed pertussis toxoid vaccine was studied in 76 000 children in the 1990s in Gothenburg, Sweden. Long-lasting itchy subcutaneous nodules at the vaccination site were seen in 745 participants. Of 495 children with itchy nodules who were patch tested for aluminium allergy, 377 were positive. In 2007-2008, 241 of the positive children were retested. Only in one third were earlier positive results reproduced. OBJECTIVES: To further describe patch test reactions to different aluminium compounds in children with vaccine-induced aluminium allergy. PATIENTS/METHODS: Positive patch test results for metallic aluminium (empty Finn Chamber) and aluminium chloride hexahydrate 2% petrolatum (pet.) were analysed in 366 children with vaccine-induced persistent itching nodules tested in 1998-2002. Of those, 241 were tested a second time (2007-2008), and the patch test results of the two aluminium preparations were analysed. RESULTS: Patch testing with aluminium chloride hexahydrate 2% pet. is a more sensitive way to diagnose aluminium contact allergy than patch testing with metallic aluminium. A general decrease in the strength of reactions to both aluminium preparations in 241 children tested twice was observed. CONCLUSIONS: Aluminium contact allergy can be diagnosed by patch testing without using metallic aluminium.
Assuntos
Compostos de Alumínio/efeitos adversos , Alumínio/efeitos adversos , Cloretos/efeitos adversos , Dermatite Alérgica de Contato/diagnóstico , Vacinas contra Difteria, Tétano e Coqueluche Acelular/efeitos adversos , Testes do Emplastro/métodos , Adjuvantes Imunológicos/efeitos adversos , Adulto , Alumínio/administração & dosagem , Cloreto de Alumínio , Compostos de Alumínio/administração & dosagem , Criança , Cloretos/administração & dosagem , Dermatite Alérgica de Contato/etiologia , Relação Dose-Resposta Imunológica , Feminino , Humanos , Masculino , SuéciaRESUMO
BACKGROUND: In studies in Gothenburg, Sweden, in the 1990s of an aluminium hydroxide-adsorbed pertussis toxoid vaccine, 745 of ~76 000 vaccinated children developed long-lasting itchy subcutaneous nodules at the vaccination site. Of 495 children with itchy nodules patch tested for aluminium allergy, 376 (76%) were positive. OBJECTIVES: To study the prognosis of the vaccine-induced aluminium allergy. PATIENTS AND METHODS: Two hundred and forty-one children with demonstrated aluminium allergy in the previous study were patch tested again 5-9 years after the initial test, with the same procedure as used previously. RESULTS: Contact allergy to aluminium was no longer demonstrable in 186 of the retested 241 children (77%). A negative test result was more common in children who no longer had itching at the vaccination site; it was also related to the age of the child, the time after the first aluminium-adsorbed vaccine dose, and the strength of the reaction in the first test. CONCLUSIONS: Patch test reactivity to aluminium seems to disappear or weaken with time.
Assuntos
Compostos de Alumínio/administração & dosagem , Dermatite Alérgica de Contato/imunologia , Dermatite Alérgica de Contato/prevenção & controle , Vacinas contra Difteria, Tétano e Coqueluche Acelular/imunologia , Adjuvantes Imunológicos/administração & dosagem , Adolescente , Criança , Dessensibilização Imunológica , Vacinas contra Difteria, Tétano e Coqueluche Acelular/administração & dosagem , Relação Dose-Resposta Imunológica , Feminino , Humanos , Masculino , Testes do Emplastro , Prognóstico , Fatores de TempoRESUMO
BACKGROUND: The Swedish Medical Products Agency (MPA) provides a voluntary reporting system for adverse reactions to cosmetics. However, the reporting is sparse, and the products involved are sometimes difficult to identify. OBJECTIVES: To investigate how often patients referred for patch testing were tested with the cosmetic products that they had been using themselves, and to improve the reporting to the MPA by the use of photographic documentation of product labels. PATIENTS AND METHODS: Consecutive patients at five dermatology departments who were patch tested with their own cosmetics were included. Reports including protocols of positive patch test results for the patients' own cosmetics and photographs/photocopies of product labels were sent to the MPA. RESULTS: Three hundred and sixteen of 948 patients (33%) were tested with their own cosmetics, and 15% of these tested positive with one or more products. The number of reports was more than three times higher than in corresponding periods in earlier years. For 79% of the products, photographs/photocopies of the containers were submitted, and for 30%, batch numbers were submitted. CONCLUSIONS: For a substantial number of patients, their own cosmetics were suspected of causing adverse reactions and were therefore tested. During the study, the number of reports to the MPA tripled, and the relevant products were easier to identify.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos , Cosméticos/efeitos adversos , Dermatite Alérgica de Contato/etiologia , Testes do Emplastro , Adolescente , Adulto , Idoso , Alérgenos/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Suécia , Adulto JovemRESUMO
Background: Vaccines adsorbed to aluminium can induce long-lasting intensely itching subcutaneous nodules (granulomas) at the injection site as well as contact allergy to aluminium. In clinical trials of a new acellular pertussis vaccine performed in the 1990s (Gothenburg, Sweden) with 76 000 participants, itching nodules were reported in 745 children. A positive patch test to aluminium was verified in 77% of the tested children with itchy nodules. Aim: To describe the long-term clinical course and prognosis of vaccine-related itching nodules caused by aluminium-containing pediatric vaccines and to estimate the risk for new symptoms after future vaccination with aluminium-containing vaccines. Methods: 745 children with vaccine-related itching nodules were followed by regular interviews/questionnaires for more than 20 years. 723 of them received a booster dose of diphtheria/tetanus vaccine either with or without aluminium adjuvant during the follow-up time. Results: Most study participants (86%) reported a full recovery from their itching nodules after a median duration of 6.6 years. Only a few of the diphtheria/tetanus-booster-vaccinated children (3%) reported mild transient itching and swelling at the new injection site. Conclusion: Vaccine-induced itching granulomas caused by an aluminium-adsorbed acellular pertussis toxoid vaccine seem to disappear over time. Future vaccinations with aluminium-adsorbed vaccines can be performed with little risk for new itching nodules later in life.
RESUMO
Sesquiterpene lactone mix detects contact allergy to these compounds present in the plant family Asteraceae. This marker is present in many baseline series. An additional marker is Compositae mix, which is not present in many baseline series. To investigate whether this allergen should be inserted into the Swedish baseline series, six dermatology centres representing the Swedish Contact Dermatitis Research Group included Compositae mix into their baseline series for 1.5 years. Of 2818 patients tested, 31 (1.1%) reacted to Compositae mix and 26 (0.9%) to Sesquiterpene lactone mix. Active sensitization to Compositae mix was noted in two cases. Only 0.4% of Asteraceae contact allergy cases would have been missed if Compositae mix had not been tested, a frequency too low to merit its inclusion in the baseline series. Due to obvious geographical differences in frequency in frequency of simultaneous allergic reactions to Compositae mix and Sesquiterpene lactone mix, the question as to whether specific baseline series (including Compositae mix or not as a "tail" substance) should be used in the different centres must be addressed. Another option could be to remove Sesquiterpene lactone mix from the baseline series and substitute it with Compositae mix.
Assuntos
Alérgenos , Asteraceae/efeitos adversos , Dermatite Alérgica de Contato/diagnóstico , Lactonas , Testes do Emplastro , Extratos Vegetais , Sesquiterpenos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Dermatite Alérgica de Contato/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Suécia , Adulto JovemRESUMO
BACKGROUND: Contact allergy to phenol-formaldehyde resins (PFRs) based on phenol and formaldehyde is not detected by a p-tertiary-butylphenol-formaldehyde resin (PTBP-FR) included in most baseline patch test series. OBJECTIVES: To investigate the rate of contact allergy to PFR-2 (a mixture of monomers and dimers from a resol resin based on phenol and formaldehyde) in a Swedish population, and to investigate associated simultaneous allergic reactions. METHODS: Five centres representing the Swedish Contact Dermatitis Research Group included PFR-2 in their patch test baseline series for a period of 1.5 years. RESULTS: Of 2504 patients tested, 27 (1.1%) reacted to PFR-2. Of those 27 individuals, 2 had a positive reaction to formaldehyde and 2 to PTBP-FR. Simultaneous allergic reactions were noted to colophonium in 6, to Myroxylon pereirae in 14, and to fragrance mix I in 15. CONCLUSIONS: The contact allergy frequency in the tested population (1.1%) merits its inclusion in the Swedish baseline series and possibly also in other baseline series. Simultaneous allergic reactions were noted to colophonium, M. pereirae, and fragrance mix I.
Assuntos
Dermatite Alérgica de Contato/diagnóstico , Formaldeído/efeitos adversos , Testes do Emplastro/métodos , Fenóis/efeitos adversos , Polímeros/efeitos adversos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Alérgenos/toxicidade , Criança , Pré-Escolar , Feminino , Formaldeído/toxicidade , Humanos , Masculino , Pessoa de Meia-Idade , Myroxylon/toxicidade , Perfumes/efeitos adversos , Resinas Vegetais/efeitos adversos , Suécia/epidemiologiaRESUMO
A susceptibility locus for psoriasis, PSORS4, has been mapped to chromosome 1q21 in the region of the epidermal differentiation complex. The region has been refined to a 115 kb interval around the loricrin (LOR) gene. However, no evidence of association between polymorphisms in the LOR gene and psoriasis has been found. Therefore, we have analysed association to three candidate gene clusters of the region, the S100, small proline-rich protein (SPRR) and PGLYRP (peptidoglycan recognition protein) genes, which all contain functionally interesting psoriasis candidate genes. In previous studies, the SPRR and S100 genes have shown altered expression in psoriasis. Also polymorphisms in the PGLYRP genes have shown to be associated with psoriasis. We genotyped altogether 29 single nucleotide polymorphisms (SNPs) in 255 Finnish psoriasis families and analysed association with psoriasis using transmission disequilibrium test. A five-SNP haplotype of PGLYRP SNPs associated significantly with psoriasis. There was also suggestive evidence of association to SPRR gene locus in Finnish families. To confirm the putative associations, selected SNPs were genotyped also in a family collection of Swedish and Irish patients. The families supported association to the two gene regions, but there was also evidence of allelic heterogeneity.
Assuntos
Proteínas de Transporte/genética , Cromossomos Humanos Par 1/genética , Heterogeneidade Genética , Psoríase/etnologia , Psoríase/genética , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Proteínas Ricas em Prolina do Estrato Córneo/genética , Feminino , Finlândia , Predisposição Genética para Doença/genética , Genótipo , Haplótipos/genética , Humanos , Lactente , Irlanda , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único/genética , Suécia , Adulto JovemAssuntos
Dermatite Alérgica de Contato/etiologia , Dermatite Ocupacional/etiologia , Dermatoses da Mão/induzido quimicamente , Sabões/efeitos adversos , beta-Alanina/análogos & derivados , Adulto , Feminino , Humanos , Propionatos/efeitos adversos , Restaurantes , Adulto Jovem , beta-Alanina/efeitos adversosRESUMO
BACKGROUND: The use of cosmetics is rising, and adverse reactions to these products are increasing. In Sweden, the Medical Products Agency (MPA) keeps a voluntary reporting system for such adverse reactions. However, the reporting is sparse, consisting almost only of cases with test-proven allergic contact dermatitis, thus under-reporting the more common irritant reactions. OBJECTIVE: The aim of the study was to try to improve the reporting system. PATIENTS AND METHODS: Dermatologists at 3 dermatology departments used a structured protocol during the clinical investigation of 151 consecutive patients reporting skin reactions to cosmetics. The protocol included symptoms, signs, affected body site, suspected products, and final diagnosis after patch testing. Based on clinical data and patch test results, a causality assessment for each product was made according to a protocol used at the MPA. RESULTS: Allergic contact dermatitis was found in 28% of the patients, and irritant reactions were equally common at 27%. CONCLUSIONS: Using this structured protocol, the cases of irritant dermatitis were also reported, and it is recommended that such a protocol is used as a standard to improve the reporting of adverse reactions to skin care products.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos/normas , Cosméticos/efeitos adversos , Dermatite Alérgica de Contato/etiologia , Dermatite Irritante/etiologia , Adolescente , Adulto , Sistemas de Notificação de Reações Adversas a Medicamentos/estatística & dados numéricos , Idoso , Idoso de 80 Anos ou mais , Causalidade , Criança , Protocolos Clínicos , Dermatite/diagnóstico , Dermatite Alérgica de Contato/diagnóstico , Dermatite Irritante/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Testes do Emplastro , Estudos Prospectivos , Medição de Risco/métodos , Pele/patologia , Estatísticas não Paramétricas , SuéciaRESUMO
We have previously reported a region on chromosome 5q as a possible susceptibility region for psoriasis. This cytokine cluster-rich region has also been suggested as a susceptibility locus in other autoimmune or inflammatory diseases including Crohn's disease (CD) and rheumatoid arthritis (RA). Three specific single-nucleotide polymorphisms (SNPs) have been reported to associate with RA and CD and to change the functional activity of two organic cation transporters, solute carrier family 22 member 4/5 (SLC22A4) and (SLC22A5). In this study, we have analyzed these SNPs for an association with psoriasis. We have also performed a denser linkage analysis of this region with an additional 31 microsatellite markers. We were not able to detect any association with any of the three SNPs analyzed. However, our linkage result supports the involvement of this region in the etiology of psoriasis. We obtained a peak non-parametric linkage value of 3.1 for marker D5S436 in a subgroup of patients with joint complaints. This result supports the findings in another study of psoriasis patients originating from Iceland in which the authors obtained a peak logarithm of the odds score of 2.6 for marker D5S2090, only 2 Mb from D5S436. This suggests a psoriasis susceptibility locus on chromosome 5q32 that is involved in the arthritic phenotype of the disease.
Assuntos
Cromossomos Humanos Par 5 , Predisposição Genética para Doença , Proteínas de Transporte de Cátions Orgânicos/genética , Polimorfismo de Nucleotídeo Único , Psoríase/genética , Mapeamento Cromossômico , Ligação Genética , Humanos , Membro 5 da Família 22 de Carreadores de Soluto , SimportadoresRESUMO
BACKGROUND: The aim of the present study was to describe the clinical characteristics of a population of psoriatics sampled from a patient organisation and not from hospitals or out-patient clinics. Furthermore, we wanted to compare siblings with and without psoriasis regarding the occurrence of other diseases. METHODS: At the end of 1991, we initiated a project which aimed to study genetic factors leading to psoriasis. Firstly, we sent questionnaires to all the members of the Swedish Psoriasis Association. We then examined 1,217 individuals (570 with psoriasis) from 310 families, in their homes in the southern part of Sweden. All the available family members were examined clinically and asked about the course of the skin disease and the occurrence of other diseases. The eight hundred members of the proband generation were divided into two groups, with or without psoriasis, and their clinical features were compared. RESULTS: Most individuals in this study population had a mild form of psoriasis. The siblings with psoriasis had joint complaints significantly more frequently than their siblings without the skin disease and those with joint complaints had more widespread skin disease. Among the other studied concomitant diseases (iritis, heart or hypertension disease, endocrine disease, inflammatory bowel disease and neurological disease), we were not able to find any difference. Seventy-seven of 570 persons were found to be in remission (13.5%). Females had a mean onset 2.5 years earlier than males. We were not able to find any correlation between the extent of the skin disease and age at onset. Twice as many persons with joint complaints were found among those with psoriasis than among those without, 28% versus 13%. Almost half (48%) the psoriatics who also had joint complaints had psoriasis lesions on their nails. Endocrine disorders were found in 9% of those without any allele for Cw6, but only in 1% of those who had Cw6. In fact, none of 183 Cw6 carriers had diabetes, as compared to the population prevalence of 3-5% in Sweden. CONCLUSION: With the exception of joint complaints, persons with psoriasis, collected from a patient organisation, did not have an increased frequency of (studied) co-existing diseases.
Assuntos
Antígenos HLA-C/genética , Psoríase/complicações , Adolescente , Adulto , Idoso , Criança , Família , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Psoríase/diagnóstico , Psoríase/genética , Inquéritos e Questionários , Suécia , Gêmeos , Instituições Filantrópicas de SaúdeRESUMO
Psoriasis is a multifactorial hereditary skin disease. The searches for causative DNA variations have generated several susceptibility loci, but at present, the gene(s) involved has not been identified. In this article, we investigated whether cystatin A, an upregulated gene in psoriatic plaques and located at chromosome 3q21, is the disease-causing gene at the psoriasis susceptibility locus PSORS5. We also investigated association to a second gene located in this region, zinc finger protein 148. The two genes have been sequenced in a small case/control set in search for SNP markers, followed by family-based association analysis using the transmission disequilibrium test. We did not detect association with either of the genes.
Assuntos
Cistatinas/genética , Proteínas de Ligação a DNA/genética , Psoríase/genética , Fatores de Transcrição/genética , Cromossomos Humanos Par 3 , Predisposição Genética para Doença , Humanos , Desequilíbrio de Ligação , Polimorfismo de Nucleotídeo Único , Regiões Promotoras Genéticas/genéticaRESUMO
During trials of aluminium adsorbed diphtheria-tetanus/acellular pertussis vaccines from a single producer, persistent itching nodules at the vaccination site were observed in an unexpectedly high frequency. The afflicted children were followed in a longitudinal observational study, and the presence of aluminium sensitization was investigated in the children with itching nodules and their symptomless siblings by patch tests. Itching nodules were found in 645 children out of about 76,000 vaccinees (0.8%) after both subcutaneous (s.c.) and intramuscular (i.m.) injection. The itching was intense and long-lasting. So far, 75% still have symptoms after a median duration of 4 years. Contact hypersensitivity to aluminium was demonstrated in 77% of the children with itching nodules and in 8% of the symptomless siblings who had received the same vaccines (P<0.001). Children with persistent itching nodules and/or aluminium sensitization should be warned about aluminium containing products (e.g. vaccines and antiperspirants). The reason for the high incidence of itching nodules after SSI vaccines is unknown and should be further investigated.
Assuntos
Alumínio/análise , Alumínio/imunologia , Vacina contra Difteria, Tétano e Coqueluche/efeitos adversos , Vacina contra Difteria, Tétano e Coqueluche/análise , Hipersensibilidade Tardia/imunologia , Prurido/imunologia , Absorção , Fatores Etários , Alumínio/administração & dosagem , Criança , Vacina contra Difteria, Tétano e Coqueluche/administração & dosagem , Etnicidade , Humanos , Hipersensibilidade Tardia/epidemiologia , Hipersensibilidade Tardia/patologia , Injeções Intramusculares , Injeções Subcutâneas , Vacinação em Massa , Prognóstico , Prurido/epidemiologia , Prurido/patologiaRESUMO
It is known that cosmetics and skin care products can cause adverse skin reactions. However, the frequency of adverse reactions reported to the Medical Product Agency (MPA) in Sweden is low. The purpose of the present study was to evaluate the occurrence of adverse skin reactions to cosmetics among patients referred for standard patch testing owing to suspected contact dermatitis in general, most frequently hand eczema. Consecutive patients at four patch test clinics in Sweden were invited to participate; 1075 were included. Of these, 47.3% (54.2% women and 30.8% men) reported current or previous adverse skin reactions to cosmetics and skin care products. This group showed significantly more positive patch test reactions, a higher prevalence of atopic dermatitis and the dermatitis was more frequently located in the face and neck region. Our results show that patients referred for standard patch testing have--or have had--a large proportion of self-reported adverse reactions to cosmetics or skin care products. We conclude that among patients with suspected contact dermatitis, adverse reactions to cosmetics can be a more important aetiological and/or complicating factor than is commonly acknowledged and that the reporting of such reactions to the MPA probably can be improved.
Assuntos
Cosméticos/efeitos adversos , Dermatite Alérgica de Contato/epidemiologia , Dermatite Alérgica de Contato/etiologia , Alérgenos/efeitos adversos , Instituições de Assistência Ambulatorial , Análise de Variância , Dermatite Alérgica de Contato/diagnóstico , Feminino , Humanos , Incidência , Masculino , Testes do Emplastro , Probabilidade , Estudos Prospectivos , Medição de Risco , Distribuição por Sexo , Inquéritos e Questionários , Suécia/epidemiologiaRESUMO
Psoriasis is a chronic inflammatory disease of the skin with both genetic and environmental risk factors. Here we describe the creation of a single-nucleotide polymorphism (SNP) map spanning 900-1200 kb of chromosome 3q21, which had been previously recognized as containing a psoriasis susceptibility locus, PSORS5. We genotyped 644 individuals, from 195 Swedish psoriatic families, for 19 polymorphisms. Linkage disequilibrium (LD) between marker and disease was assessed using the transmission/disequilibrium test (TDT). In the TDT analysis, alleles of three of these SNPs showed significant association with disease (P<0.05). A 160-kb interval encompassing these three SNPs was sequenced, and a coding sequence consisting of 13 exons was identified. The predicted protein shares 30-40% homology with the family of cation/chloride cotransporters. A five-marker haplotype spanning the 3' half of this gene is associated with psoriasis to a P value of 3.8<10(-5). We have called this gene SLC12A8, coding for a member of the solute carrier family 12 proteins. It belongs to a class of genes that were previously unrecognized as playing a role in psoriasis pathogenesis.